Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Contracts Torrey Hills Capital to Boost Awareness of Its Proprietary Cancer Visualization Technology

  • Torrey Hills Capital is a leading investor and financial public relations firm that offers extensive expertise in investor relations, corporate communications and other market support operations
  • The services provided to Imagin Medical will be overseen by Torrey Hills Founder and Principal Cliff Mastricola
  • Imagin believes its proprietary imaging technology, the i/Blue Imaging System(TM), will establish a new standard of care in visualizing cancer during minimally invasive procedures
  • Company’s current focus is bladder cancer, the 6th most prevalent form of cancer and most expensive to treat

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has engaged the services of San Diego-based investor relations firm Torrey Hills Capital, Inc. to increase awareness of its products with an informed investor audience in both the U.S. and Canadian marketplaces.

Torrey Hills Capital is a leading investor and financial PR firm that specializes in small and microcap companies. Formed in 1998, the firm offers considerable expertise and experience in corporate communications, investor relations, non-deal roadshows, as well as other market support activities (

Torrey Hills Capital will provide Imagin Medical with dedicated market awareness and investor relations services that will be overseen by Cliff Mastricola, founder and principal of the firm. Mastricola has extensive experience in advising and developing corporate finance strategies, especially debt and equity capital-related issues, as well as mergers and acquisitions, recapitalizations, valuations and helping private companies go public.

The agreement between Imagin and Torey Hills is subject to regulatory acceptance of applicable filings with the CSE. Signed for an initial period of three months at a monthly rate of $7,000, the agreement can be automatically extended if both parties are satisfied with the terms and achieved progress. Imagin also agreed to a one-time grant of 100,000 incentive stock options at a price of $0.49 (C$0.62) per share for a three-year period.

By contracting Torrey Hills Capital, Imagin Medical plans to increase public and investor awareness of its innovative imaging technology, the i/Blue Imaging System), that the company expects will establish a new standard of care in visualizing cancer during minimally invasive procedures. The company’s initial focus is bladder cancer, the sixth most prevalent forms of cancer in the United States and the most expensive one to treat, while also having one of the highest recurrence rates (

The current standard of visualizing bladder cancer during surgery uses white light illumination, which is especially effective when it comes to visualizing cancerous tumors protruding above the bladder wall. However, with this method flat tumors look the same as normal tissue. This issue is successfully overcome with the use of blue light. The problem, however, is that blue light cannot be used in real-time during surgery, and requires surgeons to constantly switch back and forth between white and blue light images to get perspective.

The proprietary i/Blue Imaging System(TM) addresses the limitations surgeons face in this regard by simultaneously displaying both white-light and blue-light images side by side, in real time. Additionally, the technology is highly versatile and can be attached to most endoscopes on the market, which means hospitals would be able to adopt the innovative visualization system without having to replace their current instruments, resulting in significant cost savings.

According to Imagin Medical, this technology has the potential to revolutionize the current standard of care for bladder cancer patients and help position the company as a leading provider of effective solutions in the global bladder cancer market, which is expected to reach $4.71 billion by 2026 ( Imagin Medical also intends to expand its technology for multiple endoscopic procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast agents and illumination sources.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050